<DOC>
	<DOCNO>NCT00890305</DOCNO>
	<brief_summary>This clinical trial perform previously untreated patient metastatic colorectal cancer . The study evaluate safety , tolerability efficacy study drug , CT-011 , combination FOLFOX chemotherapy ( FOLFOX4 mFOLFOX6 ) compare treatment FOLFOX alone .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability Efficacy FOLFOX + CT-011 Versus FOLFOX Alone</brief_title>
	<detailed_description>The propose clinical trial multi-center , randomize , open label , active control study previously untreated patient metastatic colorectal cancer aim evaluate safety , tolerability efficacy monoclonal antibody , CT-011 , administer 3mg/kg combination FOLFOX chemotherapy ( FOLFOX4 mFOLFOX6 ) compare treatment FOLFOX alone . Approximately 168 patient plan enrol study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>1 . Patient 's age 18 year old , gender . 2 . Patients metastatic disease eligible first line FOLFOX chemotherapy . Adjuvant neoadjuvant give least 12 month prior nonmetastatic disease permit . 3 . ECOG performance status ≤ 1 4 . At least 4 week prior major surgery radiotherapy . 5 . Life expectancy &gt; 3 month 6 . Hematology : ANC ≥ 1.5X109/L ; Platelets &gt; 100x109/L . 7 . Adequate Renal function 8 . Adequate Hepatic function 9 . Normal Cardiac function 1 . Patients adjuvant neoadjuvant therapy nonmetastatic disease give within last 12 month . 2 . Patients receive Oxaliplatin within 12 month prior diagnosis metastatic disease . 3 . Patients concurrent anti cancer therapy allow study . 4 . Patients concurrent steroid , allow routine antiemetic , inhale steroid 5 . Presence clinically apparent suspect brain metastasis . 6 . Patients myocardial infarction , severe congestive heart failure , significant arrhythmia within past 6 month . 7 . Serious active infection time prestudy screen . 8 . Active history autoimmune disorders/conditions . 9 . Women pregnant lactate 10 . Concurrent active malignancy . 11 . Ascites , pleural effusion , osteoblastic bone metastases site disease . 12 . Other prior malignancy , except cure adequately treated malignancy evidence activity 5 year . 13 . Subjects condition may interfere subject ' ability understand requirement study . 14 . Patients history life threaten allergic reaction food drug 15 . Patients symptomatic peripheral neuropathy &gt; Grade 1 . 16 . Known positive HIV , Hepatitis B surface antigen Hepatitis C antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>FOLFOX chemotherapy</keyword>
</DOC>